Behzad Aghazadeh bought $36.3M of Scribe Therapeutics (SCTX)
Executed Jul 24, disclosed Jul 29, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 28), the stock returned +73.4% (delay-adjusted); from the execution session (Jul 27), +73.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Behzad Aghazadeh (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Scribe Therapeutics Inc. (SCTX). Across 1 priced purchase filing, the average 21-session return was +73.4% from execution and +73.4% from disclosure (delay-adjusted; derived). The largest single filing was $36.3M of SCTX (2,391,238 sh across 3 lots, as filed), executed Jul 24.
Healthcare · Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→